Alkylating benzamides with melanoma cytotoxicity: Role of melanin, tyrosinase, intracellular pH and DNA interaction

Melanoma Research

Volumn 15, Issue 5, 2005, Pages 383-391

  Wolf, Markus ^a   Bauder Wüst, Ulrike ^a   Haberkorn, Uwe ^b   Mier, Walter ^b   Eisenhut, Michael ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Anticancer drugs; Benzamide conjugates; Chlorambucil; Chloroquine; Dacarbazine; DNA binding; Melanin binding; Melanosomal pH; Phenylisothiourea; Targeted melanoma therapy; Tyrosinase

Indexed keywords

BENZAMIDE DERIVATIVE; CHLORAMBUCIL; CHLOROQUINE; CYTOSTATIC AGENT; DACARBAZINE; DNA; DRUG CARRIER; MELANIN; MONOPHENOL MONOOXYGENASE; PHENYLISOTHIOUREA; THIOUREA DERIVATIVE; UNCLASSIFIED DRUG;

ACIDITY; ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING SITE; BIOACCUMULATION; CANCER CELL CULTURE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DNA BINDING; DRUG DNA INTERACTION; DRUG EFFECT; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TRANSPORT; ENZYME ACTIVITY; MELANOGENESIS; MELANOMA; MELANOMA CELL; MELANOSOME; MORRIS HEPATOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BENZAMIDES; CELL SURVIVAL; CHLORAMBUCIL; DNA; DRUG CARRIERS; ENZYME ACTIVATION; LIVER NEOPLASMS, EXPERIMENTAL; MELANINS; MELANOMA, EXPERIMENTAL; MICE; MONOPHENOL MONOOXYGENASE;

EID: 27644518128     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200510000-00006     Document Type: Article

References (28)

1. Eigentler TK, Caroli UM, Radny P, Garbe C. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol 2003; 4:748-759.
2. Jordan AM, Khan TH, Malkin H, Osborn HM, Photiou A, Riley PA. Melanocyte-directed enzyme prodrug therapy (MDEPT) - development of second generation prodrugs for targeted treatment of malignant melanoma. Bioorg Med Chem 2001; 9:1549-1558.
3. Inoue S, Hasegawa K, Ito S, Ozeki H, Solano F, Jimenez-Cervantes C, et al. Antimelanoma effect of 4-S-cysteaminylcatechol - an activated form of 4-S-cysteaminylphenol. Cancer Res 1995; 55:2603-2607.
4. Morrison ME, Yagi MJ, Cohen G. In vitro studies of 2,4- dihydroxyphenylalanine, a prodrug targeted against malignant melanoma cells. Proc Natl Acad Sci USA 1985; 82:2960-2964.
5. Svensson HP, Frank IS, Berry KK, Senter PD. Therapeutic effects of monoclonal antibody-beta-lactamase conjugates in combination with a nitrogen mustard anticancer prodrug in models of human renal cell carcinoma. J Med Chem 1998; 41:1507-1512.
6. Rosenblum MG, Marks JW, Cheung LH. Comparative cytotoxicity and pharmacokinetics of antimelanoma immunotoxins containing either natural or recombinant gelonin. Cancer Chemother Pharmacol 1999; 44:343-348.
7. Kerr DE, Vrudhula VM, Svensson HP, Siemers NO, Senter PD. Comparison of recombinant and synthetically formed monoclonal antibody-beta-lactamase conjugates for anticancer prodrug activation. Bioconjug Chem 1999; 10:1084-1089.
8. Morandini R, Suli-Vargha H, Libert A, Loir B, Botyanszki J, Medzihradszky K, et al. Receptor mediated cytotoxicity of α-MSH fragments containing melphalan in a human melanoma cell line. Int J Cancer 1994; 56:129-133.
9. Ghanem GE, Liberi A, Arnould R, Vercammen A, Lejeune F. Human melanoma targeting with alpha-MSH-melphalan conjugate. Melanoma Res 1991; 1:105-114.
10. Michelot JM, Moreau MCF, Veyre AJ, Bonafous JF, Bacin FJ, Madelmont JC, et al. Phase II scintigraphic clinical trial of malignant melanoma with iodine-123-N-(2-diethylaminoethyl-4-iodobenzamide). J Nucl Med 1993; 34:1260-1266.
11. 123I-IMBA for melanoma imaging. J Nucl Med 1997; 38:127-133.
12. Eisenhut M, Hull WE, Mohammed A, Mier W, Lay D, Just W, et al. Radioiodinated N-(2-diethylaminoethyl)benzamide derivatives with high melanoma uptake - structure-affinity relationships, metabolic fate, and intracellular localization. J Med Chem 2000; 43:3913-3922.
13. Wolf M, Bauder-Wüst U, Mohammed A, Schönsiegel F, Mier W, Haberkorn U, et al. Alkylating benzamides with melanoma cytotoxicity. Melanoma Res 2004; 14:353-360.
14. Gniazdowski M, Denny WA, Nelson SM, Czyz M. Transcription factors as targets for DNA-interacting drugs. Curr Med Chem 2003; 10:909-924.
15. Ancans J, Tobin DJ, Hoogduijn MJ, Smit NP, Wakamatsu K, Thody AJ. Melanosomal pH controls rate of melanogenesis, eumelanin/phaeomelanin ratio and melanosome maturation in melanocytes and melanoma cells. Exp Cell Res 2001; 268:26-35.
16. Bhatnagar V, Anjaiah S, Puri N, Darshanam BN, Ramaiah A. pH of melanosomes of B16 murine melanoma is acidic: its physiological importance in the regulation of melanin biosynthesis. Arch Biochem Biophys 1993; 307:183-192.
17. Ancans J, Thody AJ. Activation of melanogenesis by vacuolar type H(+)-ATPase inhibitors in amelanotic, tyrosinase positive human and mouse melanoma cells. FEBS Lett 2000; 478:57-60.
18. Geall JG, Blagbrough IS. Rapid and sensitive ethidium bromide fluorescence quenching assay of polyamine conjugate-DNA interactions for the analysis of lipoplex formation in gene therapy. J Pharm Biomed Anal 2000; 22:849-859.
19. Banning TP, Heard CM. Binding of doxycycline to keratin, melanin and human epidermal tissue. Int J Pharm 2002; 20:219-227.
20. Svensson SPS, Lindgren S, Powell W, Green H. Melanin inhibits cytotoxic effects of doxorubicin and daunorubicin in MOLT 4 cells. Pigment Cell Res 2003; 16:351-354.
21. Slominski A, Moellmann G, Kuklinska E. L-tyrosine, L-dopa, and tyrosinase as positive regulators of the subcellular apparatus of melanogenesis in Bomirski Ab amelanotic melanoma cells. Pigment Cell Res 1989; 2:109-116.
22. Hakozaki T, Minwalla L, Zhuang J, Chhoa M, Matsubara A, Miyamoto K, et al. The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Br J Dermatol 2002; 147:20-31.
23. Fuller BB, Spaulding DT, Smith DR. Regulation of the catalytic activity of preexisting tyrosinase in black and Caucasian human melanocyte cell cultures. Exp Cell Res 2001; 262:197-208.
24. Eberle J, Wagner M, MacNeil S. Human melanoma cell lines show little relationship between expression of pigmentation genes and pigmentary behaviour in vitro. Pigment Cell Res 1998; 11:134-142.
25. Anthony NG, Fox KR, Johnston BF, Khalaf Al, Mackay SP, McGroarty IS, et al. DNA binding of a short lexitropsin. Bioorg Med Chem Lett 2004; 14:1353-1356.
26. McGahon AJ, Costa Pereira AP, Cotter LD, Cotter TG. Chemotherapeutic drug-induced apoptosis in human leukaemic cells is independent of the Fas (APO-1/CD95) receptor/ligand system. Br J Haematol 1998; 101:539.
27. Solano-Munoz F, Penafiel R, Galindo JD. An electrometric method for the determination of tyrosinase activity. Biochem J 1985; 229:573-578.
28. Long L, Dolan ME. Role of cytochrome P450 isoenzymes in metabolism of O(6)-benzylguanine: implications for dacarbazine activation. Clin Cancer Res 2001; 7:4239-4244.